People with heart disease who take Wegovy may be getting cardiovascular protection that weight loss alone does not account for. A new analysis of the SELECT trial, published in the European Heart Journal on Sept. 23, found that changes in weight, waist size, blood sugar, blood pressure, cholesterol, inflammation, and kidney function could not fully explain why semaglutide lowered the risk of heart attacks, strokes, and cardiovascular deaths.
For patients and caregivers, the finding changes nothing about who should take the drug or how. The heart benefit itself is well established; what remains unsettled is why it happens.
